• for investors
  • for entrepreneurs
  • companies
  • news
  • about us

Calyxha’s novel therapies

Sep 9, 2020

Calyxha Biotechnologies GmbH is developing novel therapies targeting #neurodegeneration, the underlying cause of major human diseases, such as Parkinson’s disease.

https://www.calyxha.com/

 

_Latest News

HAYA Therapeutics – A new addition to LifeLink’s portfolio

HAYA Therapeutics – A new addition to LifeLink’s portfolio

May 8, 2025

AIRNA Raises Oversubscribed $155 Million Series B Financing

AIRNA Raises Oversubscribed $155 Million Series B Financing

April 1, 2025

Accure Therapeutics Announces Positive Phase 2 trial Results

Accure Therapeutics Announces Positive Phase 2 trial Results

February 5, 2025

Arda Therapeutics – A new addition to LifeLink’s portfolio

Arda Therapeutics – A new addition to LifeLink’s portfolio

October 8, 2024

Spiral Therapeutics Announces Successful Completion of  Clinical Trial for Meniere’s Disease

Spiral Therapeutics Announces Successful Completion of Clinical Trial for Meniere’s Disease

October 1, 2024

Welcome to the LifeLink team Ana Garcia Duran

Welcome to the LifeLink team Ana Garcia Duran

August 9, 2024

AiRNA – A new addition to LifeLink’s portfolio

AiRNA – A new addition to LifeLink’s portfolio

July 31, 2024

Ochre Bio announces new multi-year data licence agreement with GSK

Ochre Bio announces new multi-year data licence agreement with GSK

June 13, 2024

Spain leads clinical trials in Europe

Spain leads clinical trials in Europe

May 7, 2024

contact us

Barcelona Spain

  • Follow
  • Follow

navigate

  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us

legal conditions

  • Legal notice
  • Cookies policy
  • Privacy policy
  • Credits
  • home
  • for investors
  • for entrepreneurs
  • companies
  • news
  • about us